ライブ
Roche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical TechnologyEndpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealEndpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealEndpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3BFierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownBioPharma DiveInnovation alone is no longer enough in biopharmaBioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalabilityLonza NewsLonza and Stipple Bio strike licensing deal for precision oncology ADCs - BioXconomyRoche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.comFierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical development
eLife 2026年4月14日

Fear conditioning biases olfactory sensory neuron frequencies across generations

Fear conditioning biases olfactory sensory neuron frequencies across generations

原文
本文は利用できません。元の情報源をご確認ください。